Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit
This article was originally published in The Gray Sheet
Executive Summary
Guilford Pharmaceuticals' marketing of Gliadel Wafer for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight survival benefit, the company said after receiving the supplemental indication